Table 1.

Indications for PZ prophylaxis according to guidelines

Risk factor as an indication for PZ prophylaxis	2012 K‐NHIS (South Korea)	2013 EMA (EU)	2014 AAP (USA)
Premature
<29 weeks’ GA	6 months	6 months	12 months
29–31 weeks’ GA	6 months	6 months	NI
32–35 weeks’ GA	NI	6 months	NI
CLD	24 months	24 months	24 months
HS‐CHD	12 months	24 months	12 months
NMD	NI	NI	12 months†
CAA	NI	NI	12 months†
Profoundly immunocompromised	NI	NI	24 months†
Other risk factors	NI	NI	NI

^†Children with these risk factors may be considered for prophylaxis. AAP, American Academy of Pediatrics; CAA, congenital abnormality of airway; CLD, chronic lung disease; EMA, European Medicines Agency; GA, gestational age; HS‐CHD, hemodynamically significant congenital heart disease; K‐NHIS, National Healthcare Insurance Service in South Korea; NI, not indicated; NMD, neuromuscular disease; PZ, palivizumab.

This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.